Imaging and Hemodynamic Mechanisms of Cardiac Remodeling with SGLT2 Inhibitors Across Heart Failure Phenotypes: A Systematic Review
Background: Sodium-glucose cotransporter 2 (SGLT2) inhibitors, originally developed as glucose-lowering agents for type 2 diabetes mellitus, have been shown in large, randomized trials to improve clinical outcomes in heart failure (HF) across the ejection fraction (EF) spectrum. The imaging-derived and hemodynamic chan...